Form 4: Cytek Biosciences CTO Executes RSU Vesting Transaction

Chief Technology Officer Yan Ming acquired 22,179 shares of Cytek Biosciences common stock through the vesting of restricted stock units.

Summary

• Chief Technology Officer Yan Ming acquired a total of 22,179 shares of common stock via the vesting of multiple Restricted Stock Unit (RSU) awards.
• A total of 5,532 shares were withheld by the company to satisfy tax obligations associated with the vesting event.
• The net increase in the reporting person's beneficial ownership resulted in a total of 4,932,580 shares held.
• The transactions occurred on May 18, 2026, at a reference price of $3.55 per share for tax withholding purposes.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation activity rather than a discretionary trade.

Positives

• The transaction reflects the ongoing vesting of equity compensation for a key executive, aligning management interests with long-term shareholder value.

Negatives

• The filing indicates a routine tax-related sell-to-cover transaction, which is standard practice and not indicative of a change in sentiment.

Risks

• No specific operational or financial risks are disclosed in this ownership filing.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and tax-related sell-to-cover transactions are standard corporate governance practices for biotechnology executives and do not typically signal a change in strategic direction or market outlook.

Comparison to Industry Standards

• The use of RSU vesting schedules over a 4-year period is consistent with standard executive compensation practices in the life sciences and biotechnology sectors.
• Sell-to-cover transactions for tax obligations are standard practice among publicly traded companies to manage executive tax liabilities.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine equity compensation event.

Next Steps

• Continued vesting of remaining RSU awards according to the established 4-year schedule.

Key Dates

Keywords

Cytek Biosciences, CTKB, Insider Trading, Form 4, Equity Compensation, Restricted Stock Units